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A B S T R A C T
The peptide angiotensin IV (Ang IV) inﬂuences seizure susceptibility in rat and mouse models. Indeed,
Ang IV has been shown to protect rats from limbic seizures in the focal pilocarpine model. Moreover,
both anticonvulsive and antiepileptogenic effects of Ang IV have been reported in the acute
pentylenetetrazol (PTZ) and kindling model of generalized seizures in mice. It has been hypothesized
that the latter effects on seizures could be established via a modulatory effect on dopamine receptors in
the basal ganglia or via an indirect interaction between Ang IV and adenosine A1 receptors. However, a
possible role for insulin-regulated aminopeptidase (IRAP), the high afﬁnity binding site for Ang IV, has
not been studied yet. To unequivocally unravel the involvement of IRAP in generalized seizure
generation, we investigated the susceptibility of male IRAP wild-type (IRAP+/+) and knock-out (IRAP/)
mice to PTZ-induced seizures. Challenging these mice intravenously with PTZ resulted in signiﬁcantly
increased thresholds for myoclonic twitch and generalized clonic seizures with loss of righting reﬂexes
in IRAP/mice compared to their IRAP+/+ littermates. These behavioural data were conﬁrmed by video-
electrocorticography monitoring. Our study shows that IRAP/ mice are less sensitive to the
development of PTZ-induced seizures and suggests that IRAP is involved in generalized seizure
generation.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The renin–angiotensin system (RAS) is widely recognized as
one of the most powerful signalling systems for controlling sodium
balance, body ﬂuid volume and arterial blood pressure.1 The RAS
consists of a number of biologically active angiotensin peptides,
generated by an enzymatic cascade.2 One of the effector peptides,
angiotensin IV (Ang IV), has been shown to protect rats from limbic
seizures in the focal pilocarpine model.3 Moreover, both anticon-
vulsive and antiepileptogenic effects of Ang IV have been reportedAbbreviations: RAS, renin–angiotensin system; Ang IV, angiotensin IV; PTZ,
pentylenetetrazol; DA, dopamine; IRAP, insulin-regulated aminopeptidase;
IRAP+/+, wild-type; IRAP/, knock-out; i.p., intraperitoneal; ECoG, electrocortico-
graphy.
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doi:10.1016/j.seizure.2011.04.015in the acute pentylenetetrazol (PTZ) and kindling model of
generalized seizures in mice.4–6
PTZ is a central nervous system convulsant that inhibits gamma-
aminobutyric acid-activated ion channels.7 At low doses, PTZ
induces absence seizures while moderate doses induce clonic
seizures8 and high dosage causes tonic–clonic seizures. These
seizure episodes generally resolve in relatively short time. However,
animals receiving continuously a high dose PTZ may suffer from
generalized status epilepticus and eventually death.9 In the mouse
kindling model, subconvulsant doses of PTZ are repeatedly injected,
leading to generalized clonic or tonic–clonic seizures.10
PTZ kindling induces a compensatory increase in brain levels of
the inhibitory neuromodulator adenosine and an upregulation of its
A1 receptors, in order to diminish excitatory neurotransmission.11–13
The anticonvulsive effects of Ang IV in the acute PTZ and kindling
model in mice are suggested to be mediated by indirect interactions
of Ang IV with adenosine A1 receptors.5 Indeed, Ang IV pre-treatment
caused a downregulation of A1 receptors, possibly by suppressing
neuronal activity in brain areas involved in seizure development and
thus preventing the adaptive adenosine-mediated response.4
Another mechanism by which Ang IV could exert its anticon-
vulsive effects is by modulating dopamine (DA) receptors in thevier Ltd. All rights reserved.
Fig. 1. Video electrocorticography (ECoG) telemetry monitoring in IRAP wild-type
and knock-out mice. Representative electrocorticogram (ECoG) in IRAP+/+ (upper
panel) and IRAP/ (lower panel) mouse after intravenous infusion of PTZ. (A) Basal
ECoG, (B) myoclonic twitch ("), (C) clonic seizures with loss of righting reﬂexes ("),
(D) tonic seizures (").
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brain DA levels14,15 and to a decrease in DA receptor density.6 Ang
IV treatment prevented the development of the PTZ kindling
process and reversed the downregulation of DA receptors.6
Furthermore, Ang IV administration in the striatum caused an
increase in extracellular striatal DA levels16 and intracerebroven-
tricularly administered Ang IV protected the rats from pilocarpine
induced limbic seizures.3 The latter effect coincided with increased
hippocampal extracellular levels of DA,3 conﬁrming that Ang IV
affects the dopaminergic system.
Since, to our knowledge, Ang IV does not directly interact with
either adenosine or DA receptors, the observed anticonvulsive
effects are most likely indirect effects. Ang IV has been shown to
bind with low afﬁnity to angiotensin AT1 receptors,17,18 however,
the involvement of this receptor in seizure mechanisms remains
controversial.19,20 In contrast, the role of the high afﬁnity binding
site of Ang IV, insulin-regulated aminopeptidase (IRAP),21 in the
anticonvulsive effects of Ang IV has not been studied before.
IRAP is a membrane-associated zinc-dependent metallopepti-
dase of the M1 family with characteristic extracellular catalytic
and transmembrane domains but a unique cytoplasmatic amino-
terminal tail.22,23 Ang IV is a potent and competitive IRAP inhibitor,
binding to the catalytic site of this enzyme24 and has been shown
to decrease seizure severity in PTZ models, as described above.
Taken together, these data suggest a possible IRAP mediated
anticonvulsive effect. Therefore, in the present study, we compared
the susceptibility to PTZ-induced generalized seizures in mice in
which the IRAP gene was deleted, comparing their responses to the
wild-type littermate controls.
2. Materials and methods
2.1. Animals
Male insulin-regulated aminopeptidase wild-type (IRAP+/+) and
knock-out (IRAP/) mice of three to six months old were used. IRAP
mice were generated by Ozgene (Ozgene Ptd Ltd., Bentley DC,
Australia) as described before21 and bred at the animal house of the
Vrije Universiteit Brussel. Mice used in the experiments were
offspring from heterozygous IRAP breeding pairs on a C57Bl/6
background. The mice were housed under a constant light and dark
cycle (lights on at 0700 h and off at 2100 h) and were given free
access to food and water. Genotypes were determined by PCR with
the REDExtract-N-Amp Tissue PCR Kit (Sigma, St-Louis, MO, USA)
following the manufacturers’ instructions, with the following
primer pairs: for IRAP+/+ 50 GATAAGATAGAAGTAGGGGAGA 30 and
50 CAATAGAGGTACAGTCACCA 30 and for IRAP/ 50 CAATAGAGG-
TACAGTCACCA 30 and 50 GGAGAATAAGGGCTGTGAGAGA 30. All
experiments were approved by the Ethical Committee for Animal
Experiments of the Faculty of Medicine and Pharmacy of the Vrije
Universiteit Brussel.
2.2. Video electrocorticography (ECoG) telemetry monitoring
IRAP+/+ and IRAP/ mice (n = 3 for each group) were anesthe-
tized by an intraperitoneal (i.p.) injection of xylazine (Bayer, Sint-
Truiden, Belgium)/ketamine (Ceva, Brussel, Belgium) (10/100 mg/
kg). Through an incision in the abdomen and the scalp, a
transmitter (model TA10EA-F20, Data Science International, St
Paul) was placed in the abdomen and electrical leads of the
transmitter were tunnelled to the skull. Animals were placed on a
stereotaxic frame in order to ﬁx screws, connected to the leads, in
the skull at following coordinates: lateral, 2.0/+2.0; anterior
posterior, 2.1. The electrodes and screws were covered with
dental acrylic cement (Dentsply Caulk, Milford, USA). After the
surgery, mice were given ketoprofen (4 mg/kg, i.p.; Merial, Essex,United Kingdom) and were allowed to recover for 7 days in the
animal house. During this period, amoxicillin (1 mg/kg; Fort Dodge
Animal Health Benelux, Naarden, Netherlands) was administered
i.p. twice daily. The basal ECoG of the animals was measured
overnight for at least 12 h. One week after surgery, these mice were
subjected to PTZ-induced seizures as described below in Section
2.3. The obtained ECoG spectra were analyzed using Notocord-hem
Evolution1 software (Notocord, Croissy, France).25
Fig. 2. Seizure severity assessment in IRAP wild-type and knock-out mice. Pentylenetetrazol (PTZ) seizure thresholds in male IRAP+/+ and IRAP/mice. PTZ was administered
continuously via the lateral tail vein at 150 ml/min until death. The results are expressed as the mean  SEM for the thresholds of myoclonic twitch (A, n = 8), clonic seizures with
loss of righting reﬂexes (B, n = 16) and tonic hindlimb extension (C, n = 8). *p < 0.05 versus controls (two-tailed Mann–Whitney).
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The experiments for the assessment of PTZ seizure thresholds
were conducted with separate groups of unanesthesized mice
(n = 8 or n = 16 for each group). Mice were restrained and a 29 G
needle, attached to a polyethylene tubing (Smiths, Keene, USA),
was inserted into the lateral tail vein. The needle was secured to
the tail with tape and the tubing was connected to a 2.5 ml
Hamilton syringe mounted to a CMA infusion pump (Microdialysis,
Solna, Sweden). While PTZ (Sigma, St-Louis, MO, USA) solution
(7.5 mg/ml) was infused at a constant rate of 150 ml/min, the
animal was able to move freely in a cage made of Plexiglas.
The behavioural endpoints were (i) myoclonic twitch, (ii)
generalized clonic phase with loss of righting reﬂexes and (iii) tonic
hindlimb extension. The time from the start of the infusion to the
onset of each behaviour was recorded. The threshold doses were
calculated with the following formula: PTZ threshold dose (mg/
kg) = (PTZ concentration (mg/ml)  infusion rate (ml/s)  infusion
duration (s)  1000)/weight of mouse (g).25
2.4. Data analysis
Data were analyzed by using the non-parametric two-tailed
Mann–Whitney’s test (a = 0.05).
3. Results
The occurrence of seizure events in IRAP+/+ and IRAP/ mice
was assessed by an investigator blinded to the genotype. This
visual scoring system was validated by using video electrocortico-graphy (ECoG) telemetry monitoring. The representative basal
ECoG pattern of an IRAP/ mouse (Fig. 1A lower panel) did not
show any abnormalities in comparison to the IRAP+/+ mouse
(Fig. 1A upper panel). The intravenous infusion of PTZ at a constant
ﬂow rate of 150 ml/min elicited a stereotyped seizure response.
The ECoG showed an array of epileptiform activities that started
with a myoclonic twitch (Fig. 1B, indicated with arrow), followed
by clonic seizures (Fig. 1C) with loss of righting reﬂexes (Fig. 1C,
indicated with arrow) and tonic seizures (Fig. 1D, indicated with
arrow). The behaviours progressed rapidly from one stage to the
other as the infusion progressed. Thus the observed seizure events
coincided with ECoG abnormalities.
To investigate the involvement of IRAP in seizure generation,
PTZ dose thresholds were determined for each behaviour
associated with the epileptiform activities described above, in
IRAP+/+ and IRAP/ mice. Only body weight and duration of
infusion were required for the calculations, since PTZ dose and
infusion rates are constant for all animals (see Section 2.3).
Compared to IRAP+/+ mice, IRAP/ mice showed signiﬁcantly
increased PTZ thresholds for myoclonic twitch (Fig. 2A) and
generalized clonic seizures with loss of righting reﬂexes (Fig. 2B)
but not for tonic hindlimb extension (Fig. 2C).
4. Discussion
The results of this study show that the deletion of IRAP in mice
is accompanied with a lower susceptibility to PTZ-induced
seizures. The underlying molecular mechanism of this anticonvul-
sive effect against generalized seizures is not yet elucidated.
However, we can speculate based on what is known about IRAP.
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vesicles where the amino terminus projects in the cytoplasm and the
catalytic domain is present in the lumen.22 It has been hypothesized
that the binding of ligands to IRAP increases the translocation and
positioning of GLUT4 at the membrane, resulting in an increased
glucose uptake26 which could offer protection against seizures.
However, it has been described that IRAP/ mice show normal
glucose uptake27 and maintain normal glucose homeostasis,28
indicating that this mechanism is unlikely to explain the lower
susceptibility of these mice to generalized seizures.
IRAP has been identiﬁed as the high afﬁnity binding site for Ang
IV21 and could be involved in mediating anticonvulsive effects via
two remaining possible mechanisms. First, IRAP may act as a
receptor which, upon binding of the ligand to its C-terminal
domain, interacts with cytoplasmatic proteins. Ang IV and other
IRAP ligands would act as agonists to induce IRAP dimerisation and
elicit intracellular signalling22,29–31 that could result in anticon-
vulsive effects. Second, the catalytic activity of IRAP can be
inhibited by its ligands, leading to an increased half-life of
neuropeptide substrates, which potentiate biological effects.32
This hypothesis is supported by in vitro studies in which IRAP is
known to cleave a number of small neuropeptides, such as
substance P, met-enkephalin and somatostatin-14.33 In line with
this hypothesis, it is possible that the levels of some of these
circulating neuropeptides could be higher in IRAP/ mice in
comparison with IRAP+/+ mice and could explain the anticonvul-
sive effects that accompany IRAP deletion.
In conclusion, our data attribute an important role to IRAP in the
generation of generalized seizures, suggesting that IRAP is a
potential therapeutic target in epilepsy research. However, the
exact mechanism by which IRAP deletion leads to anticonvulsive
effects remains speculative and requires further work.
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